Akihiko Yoshida

National Cancer Centre Japan — Japan

Medicine · Health Sciences

56h-index11.3kcitations522works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(270), Protein Degradation and Inhibitors(107), Lymphoma Diagnosis and Treatment(74), Glioma Diagnosis and Treatment(60), Bone Tumor Diagnosis and Treatments(57)

Publications521 total

Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Figure S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Figure S4A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S8 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Figure S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Figure S4B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Figure S3 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Figure S5 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S3A-B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
2025Open Access
Genomic Profiling of Pediatric Solid Tumors With a Dual <scp>DNA</scp> / <scp>RNA</scp> Panel: <scp>JCCG‐TOP2</scp> Study
Cancer Science·2025Open Access
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907)
European Journal of Cancer·2025
Prognostic Stratification of Standard Responders to Neoadjuvant Chemotherapy in Patients with Osteosarcoma Using 18F-FDG PET/CT Imaging
JBJS Open Access·2025Open Access
Ulcerated nodular fasciitis of the finger mimicking soft tissue sarcoma: a case report
International Cancer Conference Journal·2025Open Access
page 1 of 27Next →

Frequent Co-authors

Akira Kawai(19), Hisao Asamura(12), Koji Tsuta(11), Takashi Kohno(11), Hitoshi Tsuda(11), Eisuke Kobayashi(10), Koh Furuta(10), Hitoshi Ichikawa(9), Toru Motoi(8), Tatsuhiro Shibata(8), Nobuyoshi Hiraoka(7), Susumu Wakai(7), Yoshitaka Narita(6), Ryoji Kushima(6), André L. Moreira(5), Giuseppe Pelosi(5), Mary Beth Beasley(5), Alain Borczuk(5), Jin-Haeng Chung(5), Sanja Đačić(5)